Evaluation of sICAM-1, sVCAM-1, and sE-selectin levels in patients with metastatic breast cancer receiving high-dose chemotherapy

Stem Cells and Development

Volumn 13, Issue 3, 2004, Pages 281-294

  Bewick, Mary A ^a,c   Conlon, M ^a   Lee, H ^a   Parissenti, A M ^a   Zhang, L ^a   Gluck S ^b   Lafrenie, R M ^a  

^a Northeastern Ontario Regional Cancer Centre   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS ANTIGEN; FLUOROURACIL; INTERCELLULAR ADHESION MOLECULE 1; MITOXANTRONE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VINBLASTINE;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; DISEASE PROGRESSION; E-SELECTIN; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 2942618758     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/154732804323099217     Document Type: Article

References (57)

1. Koch AE, MM Halloran, CJ Haskell, MR Shah and PF Polverini. (1995). Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376:517-519.
2. Gho YS, HK Kleinman and G Sosne. (1999). Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res 59:5128-5132.
3. Gho YS, PN Kim, HC Li, M Elkin and HK Kleinman. (2001). Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res 61:4253-4257.
4. Fox SB, GD Turner, KC Gatter and AL Harris. (1995). The increased expression of adhesion molecules ICAM-3, E- and P- selectins on breast cancer endothelium. J Pathol 177:369-376.
5. Christiansen I, C Sundstrom and TH Totterman. (1998). Elevated serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) closely reflect tumour burden in chronic B-lymphocytic leukaemia. Br J Haematol 103:1129-1137.
6. Christiansen I, C Sundstrom, G Enblad and TH Totterman. (1998). Soluble vascular cell adhesion molecule-1 (sVCAM-1) is an independent prognostic marker in Hodgkin's disease. Br J Haematol 102:701-709.
7. Wang X, C Clowes, R Duarte and QQ Pu. (2000). Serum ICAM-1 concentrations following conventional dose consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell rescue. Int J Oncol 17:591-595.
8. Maeda K, SM Kang, T Sawada, Y Nishiguchi, M Yashiro, Y Ogawa, M Ohira, T Ishikawa and CK Hirakawa-YS. (2002). Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. Oncol Rep 9:511-514.
9. Becker JC, R Dummer, AA Hartmann, G Burg and RE Schmidt. (1991). Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol 147:4398-4401.
10. Zhang GJ and I Adachi. (1999). Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. Int J Oncol 14:71-77.
11. Thompson EW and JT Price. (2002). Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin Ther Targets 6:217-233.
12. Osborn L, C Hession, R Tizard, C Vassallo, S Luhowskyj, G Chi-Rosso and R Lobb. (1989). Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59:1203-1211.
13. Nguyen M, CL Corless, BM Kraling, C Tran, T Atha, J Bischoff and SH Barsky. (1997). Vascular expression of E-selectin is increased in estrogen-receptor-negative breast cancer: a role for tumor-cell-secreted interleukin-1 alpha. Am J Pathol 150:1307-1314.
14. Gearing AJ and W Newman. (1993). Circulating adhesion molecules in disease. Immunol Today 14:506-512.
15. Banks RE, AJ Gearing, IK Hemingway, DR Norfolk, TJ Perren and PJ Selby. (1993). Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 68:122-124.
16. Hoffmann R, A Franzke, J Buer, S Sel, K Oevermann, A Duensing, M Propst, S Duensing, H Kirchner, A Ganser and J Atzpodien. (1999). Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer 79:1742-1745.
17. Byrne GJ and NJ Bundred. (2000). Surrogate markers of tumoral angiogenesis. Int J Biol Markers 15:334-339.
18. Araki T, C Miki and M Kusunoki. (2001). Biological implications of circulating soluble intercellular adhesion molecule-1 in colorectal cancer patients. Scand J Gastroenterol 36:399-404.
19. Harning R, E Mainolfi, JC Bystryn, M Henn, VJ Merluzzi and R Rothlein. (1991). Serum levels of circulating intercellular adhesion molecule I in human malignant melanoma. Cancer Res 51:5003-5005.
20. Dosquet C, MC Coudert, E Lepage, J Cabane and F Richard. (1997). Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 3:2451-2458.
21. De Vita F, S Infusino, A Auriemma, M Orditura and G Catalano. (1998). Circulating levels of soluble intercellular adhesion molecule-1 in non-small cell lung cancer patients. Oncol Rep 5:393-396.
22. Regidor PA, R Callies, M Regidor and AE Schindler. (1998). Expression of the cell adhesion molecules ICAM-1 and VCAM-1 in the cytosol of breast cancer tissue, benign breast tissue and corresponding sera. Eur J Gynaecol Oncol 19:377-383.
23. Hebbar M and JP Peyrat. (2000). Significance of soluble endothelial molecule E-selectin in patients with breast cancer. Int J Biol Markers 15:15-21.
24. Hebbar M, F Revillion, MM Louchez, C Fournier, J Bonneterre and JP Peyrat. (1999). Prognostic value of circulating soluble E-selectin concentrations in node-negative breast cancer patients. Clin Cancer Res 5:1427-1433.
25. Lei KI and PJ Johnson. (2000). The prognostic significance of serum levels of soluble intercellular adhesion molecules-1 in patients with primary extranodal non-Hodgkin lymphomas. Cancer 89:1387-1395
26. Callet N, J Delaunay and MF Pichon. (2000). Serum sICAM-1 (soluble intercellular adhesion molecule-1) and M-CSF (macrophage colony-stimulating growth factor) throughout monitoring of 34 non-serous ovarian cancers. Eur J Gynaecol Oncol 21:135-140.
27. Vuoristo MS, S Laine, H Huhtala, LM Parvinen, M Hahka-Kemppinen, M Korpela, E Kumpulainen and P Kellokumpu-Lehtinen. (2001). Serum adhesion molecules and interleukin-2 receptors as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 37:1629-1634.
28. Hatzistilianou M, F Athanassiadou, C Agguridaki and D Catriu. (1997). Circulating soluble adhesion molecule levels in children with acute lymphoblastic leukaemia. Eur J Pediatr 156:537-540.
29. Glück S, C Germond P, Lopez, P Cano, M Dorreen, T Koski, A Arnold, H Dulude and G Gallant. (1998). A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer. Eur J Cancer 34:1008-1014.
30. Bewick M, T Chadderton, M Conlon, R Lafrenie, D Morris, D Stewart and S Glück. (1999). Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bone Marrow Transplant 24:377-384.
31. Bewick M, M Conlon, S Gerard, H Lee, AM Parissenti, L Zhang, S Glück and RM Lafrenie. (2001) HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support. Bone Marrow Transplant 27:847-853.
32. Bewick M, M Conlon, AM Parissenti, H Lee, L Zhang, S Glück and RM Lafrenie. (2001). Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J Hematother Stem Cell Res 10:759-768.
33. Glück, S. (1995). Autologous transplantation for patients with advanced breast cancer with emphasis on bony metastasis. Can J Oncol 5 (Suppl 1):58-62.
34. Kaplan EL and P Meier. (1998). Nonparametric estimation form incomplete observations. J Am Stat Assoc 53:457-481.
35. Cox DR. (1972). Regression models and life-tables (with discussion). J Roy Stat Soc Ser B 34:187-220.
36. Lipton A, SM Ali, K Leitzel, L Demers, V Chinchilli, L Engle, HA Harvey, C Brady, CM Nalin, M Dugan, W Carney and J Allard. (2002). Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20:1467-1472.
37. Harris LN, V Liotcheva, G Broadwater, MJ Ramirez, P Maimonis, S Anderson, T Everett, D Harpole, MB Moore, DA Berry, D Rizzeri, JJ Vredenburgh and RC Bentley. (2001). Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 19:1698-1706.
38. Ross JS and JA Fletcher. (1999). The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 9:125-138.
39. Pegram MD, G Pauletti and DJ Slamon. (1998). HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52:65-77.
40. Yamauchi H, V Stearns and DF Hayes. (2001). The Role of c-erbB-2 as a predictive factor in breast cancer. Breast Cancer 8:171-183.
41. Sahin AA. (2000). Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol 7:158-166.
42. Hortobagyi GN. (2001). Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 28:43-47.
43. Lohrisch C and M Piccart. (2001). HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2:129-135.
44. Leek RD. (2001). The prognostic role of angiogenesis in breast cancer. Anticancer Res 21:4325-4331.
45. Benekli M, IH Gullu, G Tekuzman, MC Savas, M Hayran, G Hascelik and D Firat. (1998). Circulating intercellular adhesion molecule-1 and E-selectin levels in gastric cancer. Br J Cancer 78:267-271.
46. Velikova G, RE Banks, A Gearing, I Hemingway, MA Forbes, SR Preston, NR Hall, M Jones, J Wyatt, K Miller, U Ward, J Al Maskatti, SM Singh, PJ Finan, NS Ambrose, JN Primrose and PJ Selby. (1998). Serum concentrations of soluble adhesion molecules in patients with colorectal cancer. Br J Cancer 77:1857-1863.
47. Klein B, I Levin, B Kfir, M Mishaeli, J Shapira and T Klein. (1995). The significance of soluble interleukin-2, soluble interleukin-2 receptors, soluble ICAM-1 and beta 2-microglobulin in breast cancer patients. Tumour Biol 16:290-296.
48. Altomonte M, E Fonsatti, E Lamaj, I Cattarossi, A Cattelan and M Maio. (1999). Differential levels of soluble intercellular adhesion molecule-1 (SICAM-1) in early breast cancer and benign breast lesions. Breast Cancer Res Treat 58:19-23.
49. Merendino, RA, S Gangemi, A Ruello, A Bene, E Losi, G Lonbardo and F Purello-Dambrosio. (2001). Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int J Biol Markers 16:126-129.
50. Sun JJ, XD Zhou, YK Liu, ZY Tang, JX Feng, G Zhou, Q Xue and J Chen. (1999). Invasion and metastasis of liver cancer: expression of intercellular adhesion molecule 1. J Cancer Res Clin Oncol 125:28-34.
51. Maurer CA, H Friess, B Kretschmann, S Wildi, C Muller, H Graber, M Schilling and MW Buchler. (1998). Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. Int J Cancer 79:76-81.
52. Dosquet C, Y Chen, J Makke, JM Miclea, MC Coudert, JP Marolleau, JP Fermand, P Cottu, JP Lotz and M Benbunan. (2001). Cytokines and vascular cell adhesion molecule-1 in the blood of patients undergoing HPC mobilization. Transfusion 41:206-212.
53. Ali S, J Kaur and KD Patel. (2000). Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation. Am J Pathol 157:313-321.
54. Ogawa Y, K Hirakawa, B Nakata, T Fujihara, T Sawada, Y Kato, K Yoshikawa and M Sowa. (1998). Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res 4:31-36.
55. Kuper H, HO Adami and D Trichopoulos. (2000). Infections as a major preventable cause of human cancer. J Intern Med 248:171-183.
56. Hebbar M, F Revillion, MM Louchez, MO Vilain, C Fournier, J Bonneterre and JP Peyrat. (1998). The relationship between concentration of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer. Clin Cancer Res 4:373-380.
57. Wittig BM, H Kaulen, R Thees, C Schmitt, P Knolle, J Stock, KH Meyer zum Buschenfelde and W Dippold. (1996). Elevated serum E-selectin in patients with liver metastases of colorectal cancer. Eur J Cancer 32A:1215-1218.